Retrograde isolated hepatic perfusion:Phase 1 trial
Phase 1
- Conditions
- malignant liver neoplasm in advanced stage
- Registration Number
- JPRN-UMIN000007230
- Lead Sponsor
- ippon medical school
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1 Contraindication to angiography (due to severe side effect of contrast media) 2 High risk for general anesthesia 3 Advanced heart disease 4 Tumor invasion to Inferior vena cava or Portal vein trunk 5 Vascular anatomy not suitable for catheterization
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse effect within 4 weeks after the procedure 5-year survival rate
- Secondary Outcome Measures
Name Time Method Assessment of the change in tumor burden 4 and 12 weeks after the procedure according to RECIST criteria